Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

191 - NK/T Cell Lymphoma, Nasal Type in a Filipino Male


24 Nov 2018


Poster display - Cocktail


Tumour Site



Amabelle Trina Gerona


A.T.B. Gerona

Author affiliations

  • Medical Oncology, ST. Luke's Medical Center, 11104 - Quezon City/PH


Abstract 191

Case Summary

Extranodal NK/T cell lymphoma, nasal type is a rare aggressive, locally destructive disease. It represents 7-10% of all non-Hodgkin lymphomas with 40% 1-year survival rate. We report a 44 year old Filipino male who presented with one year history of foul smelling left nasal discharge. Physical examination was unremarkable except for ~1 x 1 cm cavity at the soft palate. Several consult were done, given nasal drops and antibiotics with no relief. Nasopharyngeal CT scan revealed a 5.2 x 3.1 cm soft tissue mass at left nasal cavity extending into the contralateral nasal cavity, no intracranial extension. After three unremarkable nasal biopsies, histopathology revealed round cell neoplasm, with immunohistochemical stains consistent with NK/T cell lymphoma Nasal type. Metastatic work up were all unremarkable. He then underwent concurrent chemotherapy with cisplatin and radiotherapy (30cGY). The palatal cavity increased in size 3 x 3 cm after completion of radiotherapy, however, the soft tissue mass decreased in size hence three cycles of etoposide, ifosfamide, cisplatin, dexamethasone were given. Patient remained asymptomatic, with a good performance status. Nasal endoscopy and nasopharyngeal MRI done post-treatment showed no evidence of lesion with stable palatal cavity defect. CT scan of chest revealed a left upper lobe non-calcified 2cm nodule with bilateral subpleural nodules.

In a rare yet aggressive malignancy such as NK/T cell lymphoma wherein the primary lesion had good response to treatment, a new lung lesion could impose progressive disease such as metastasis. We could either treat the patient as a case of progressive disease and subject him to a battery of chemotherapy or we could biopsy the new lesion. Either way, delay in diagnosis causes undue anxiety and uncanny cost to the patient. In our case, biopsy was done and indeed it was of infectious in origin. The malignancy responded well to treatment.

Editorial acknowledgement

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.